CYTOCARES

No One Fights Alone

CYTOCARES

No One Fights Alone

CYTOCARES

No One Fights Alone

CytoCares

The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.

CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor.

Learn More
30+

Partners

60+

Honors

Pipeline

CC312(anti-CD19×CD3×CD28)

Learn More
Join Us
Learn More